Latent Value Finds a Home

Having refocused its R&D exclusively on immunology as part of a cost-cutting effort, ZymoGenetics Inc. hopes to unlock some downstream value by out-licensing rights to a collection of shelved programs to Seattle Life Sciences Inc. The newco was set up expressly to develop the preclinical assets by way of venture financing and/or partnership.

ZymoGenetics last week granted Seattle Life Sciences exclusive worldwide rights to eight programs, including three mAbs

Read the full 685 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE